Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ibio ( (IBIO) ) has shared an announcement.
On April 8, 2026, iBio announced it had received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, clearing the way for a first-in-human Phase 1 trial of its anti-myostatin antibody IBIO-600 in overweight and obese adults. The randomized, double-blind, placebo-controlled, single ascending dose study is intended to assess safety, tolerability, pharmacokinetics and pharmacodynamics, with first participants expected to be dosed in the second quarter of 2026.
The trial marks iBio’s transition into a clinical-stage company and underscores its ambition to address muscle loss associated with GLP-1-based weight-loss therapies by preserving lean mass and improving body composition. The regulatory milestone in Australia also triggers the 30-trading-day countdown to the May 12, 2026 expiration of certain Series G warrants issued in the company’s August 19, 2025 financing, potentially influencing iBio’s capital structure if remaining warrants are exercised before they lapse.
The most recent analyst rating on (IBIO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.
Spark’s Take on IBIO Stock
According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.
The score is weighed down primarily by weak financial performance—minimal revenue, deep losses, and ongoing cash burn—alongside bearish technical trends (below key moving averages and negative MACD). Corporate events provide some support via pipeline progress and funding, but they do not fully offset the current fundamentals; valuation is difficult to assess due to negative earnings and no stated dividend yield.
To see Spark’s full report on IBIO stock, click here.
More about Ibio
iBio, Inc. is a San Diego-based, AI-driven biotechnology company that leverages advanced computational biology and proprietary 3D modeling to develop next-generation antibody therapeutics. Its pipeline targets cardiometabolic and cardiopulmonary diseases, obesity, cancer and other hard-to-treat conditions, with a focus on addressing significant unmet medical needs in precision medicine.
iBio is positioning itself as a cutting-edge player in the biopharmaceutical sector by integrating AI into drug discovery and development. The company aims to accelerate development timelines and build a portfolio of breakthrough monoclonal antibody treatments, including candidates designed to complement existing obesity therapies and improve overall body composition outcomes.
Average Trading Volume: 1,381,293
Technical Sentiment Signal: Strong Sell
Current Market Cap: $72.89M
Find detailed analytics on IBIO stock on TipRanks’ Stock Analysis page.